New approach methodologies: modern science for safer, smarter testing

Preclinical science is having its renaissance. New Approach Methodologies (NAMs) — human cell-based systems such as organoids and organ-on-chip devices, alongside computational and AI-enabled models — are maturing into serious tools for safety and efficacy assessment. Regulators are actively encouraging this evolution: the US Food and Drug Administration maintains a dedicated NAMs programme and in 2025 published a roadmap for integrating these methods into preclinical safety evaluation.^[1]

Why the momentum is real

• Human relevance. Systems built from human cells can capture human-specific biology, complementing traditional models where translation has historically been hardest.
• Mechanistic insight. Microphysiological systems let scientists watch mechanisms unfold — not just record outcomes — sharpening both discovery and safety science.
• Scale and speed. In-silico screening and high-throughput human-cell assays evaluate candidates earlier and faster, focusing resources on the most promising molecules.
• Ethical progress. Reducing reliance on animal studies where validated alternatives exist aligns science with widely shared values — a rare win-win.

The validation road

The field’s central task is confidence-building: demonstrating, method by method and context by context, that NAMs predict human outcomes reliably enough to inform decisions. That means reference datasets, reproducibility across laboratories, and transparent qualification — patient work that turns innovation into accepted evidence.

From the 3Rs to a regulatory movement

The ethical framework arrived first: Russell and Burch’s 1959 principles of replacement, reduction and refinement gave animal research its enduring conscience. For decades, progress meant refining within the old paradigm — until the science itself changed. Human cell culture matured from flat monolayers into three-dimensional organoids; microfluidic engineering produced organ-on-chip systems in which human tissues experience flow, stretch and interaction; and computational toxicology learned to predict properties from structure at scale. Regulators moved with the science: legislation such as the US FDA Modernization Act 2.0 of 2022 removed the categorical animal-testing requirement for new drugs, and agencies on both continents now run structured programmes to qualify new approach methodologies for regulatory use.

The motivation is scientific as much as ethical. Animal models, however carefully used, are imperfect predictors of human response — a translational gap every drug developer knows intimately. Methods built from human biology promise, where validated, to predict human outcomes better, faster and earlier.

The qualification discipline

• Context of use before everything. A NAM is qualified for a defined question — this assay, predicting this toxicity, in this decision context — not certified as a universal animal replacement.
• Reproducibility across laboratories. Inter-lab transferability studies, reference compounds and defined performance standards — the unglamorous machinery of regulatory trust.
• Integrated approaches. In practice, batteries of complementary methods — in vitro, in silico, exposure modelling — are combined into weight-of-evidence frameworks rather than single-assay verdicts.
• Early dialogue with authorities. Qualification advice pathways exist precisely so developers invest in methods regulators can eventually accept.

Looking ahead

Expect a long coexistence, not a cliff-edge: NAMs claiming territory assay by assay as validation accumulates, with animal studies persisting where integrated whole-organism biology still has no substitute. The binding constraint is, again, people — toxicologists, engineers and regulatory scientists fluent in both the new methods and the evidence standards that govern them. For the translational community, NAMs are not a niche: they are the retooling of safety science itself.

Where EUSTM fits

The EUSTM Academy’s Professional Certification in Translational Medicine (PCTM) frames exactly this bench-to-decision pathway, while the Professional Certification in Clinical Research (PCCR) connects preclinical insight to the human studies it informs.

Disclaimer. This Expert Insight is provided by EUSTM for general informational and educational purposes only. It does not constitute medical, clinical, legal, regulatory or other professional advice, and it should not be relied upon as the basis for clinical, regulatory or business decisions. While care is taken in preparing this content, EUSTM makes no representation or warranty as to the accuracy, completeness or currency of any scientific, medical or other statements, and accepts no liability arising from the use of this content. Readers should consult the cited sources, the current official guidance of the relevant authorities and frameworks, and appropriately qualified professionals in their own jurisdiction. References to third-party organisations, publications or frameworks are for information only and do not imply affiliation or endorsement.

← All Expert Insights